Respiratory drug condensation aerosols and methods of making and using them
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/12
A61K-009/14
A61M-015/00
출원번호
UP-0719899
(2003-11-20)
등록번호
US-7550133
(2009-07-01)
발명자
/ 주소
Hale, Ron L.
Lloyd, Peter M.
Lu, Amy T.
Rabinowitz, Joshua D.
Wensley, Martin J.
출원인 / 주소
Alexza Pharmaceuticals, Inc.
대리인 / 주소
Swanson & Bratschun, L.L.C.
인용정보
피인용 횟수 :
27인용 특허 :
76
초록▼
Described herein are respiratory drug condensation aerosols and methods of making and using them. Kits for delivering condensation aerosols are also described. The respiratory drug aerosols typically comprise respiratory drug condensation aerosol particles. In some variations the respiratory drug co
Described herein are respiratory drug condensation aerosols and methods of making and using them. Kits for delivering condensation aerosols are also described. The respiratory drug aerosols typically comprise respiratory drug condensation aerosol particles. In some variations the respiratory drug compound is selected from the group consisting of β-adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors, asthma antagonists, anti-endothelin drugs, prostacyclin drugs, ion channel or pump inhibitors, enhancers, or modulators and pharmaceutically acceptable analogs, derivatives, and mixtures thereof. Methods of treating a respiratory ailment using the described aerosols are also described. In general, the methods typically comprise the step of administering a therapeutically effective amount of respiratory drug condensation aerosol to a person with a respiratory ailment. Methods of forming a respiratory drug condensation aerosol are also described. The methods comprise the steps of vaporizing and condensing a respiratory drug composition.
대표청구항▼
What we claim is: 1. A composition for delivery of a drug, the compostion comprising a condensation aerosol a) wherein the condensation aerosol is formed by heating a thin film of a drug composition to produce a vapor, and condensing the vapor to form a condensation aerosol comprising the drug, b)
What we claim is: 1. A composition for delivery of a drug, the compostion comprising a condensation aerosol a) wherein the condensation aerosol is formed by heating a thin film of a drug composition to produce a vapor, and condensing the vapor to form a condensation aerosol comprising the drug, b) wherein the condensation aerosol comprises particles that are characterized by less than 10% drug degradation products by weight, c) wherein the condensation aerosol has an MMAD of less than 5 microns, and d) wherein the drug is selected from the group consisting of albuterol, epinephrine, metaproterenol, terbutaline, pseudoephedrine hydrochloride, bambuterol, bitolterol, carbuterol, clenbuterol, clorprenalin, dioxethedrine, eprozinol, etefedrine, ethylnorepinephrine, fenoterol, fenspiride, hexoprenaline, isoetharine, isoproterenol, mabuterol, methoxyphenamine, pirbuterol, procaterol, protokylol, rimiterol, salmeterol, soterenol, tretoquinol, tulobuterol, theophylline, aminophylline, acefylline, bamifylline, doxofylline, dyphylline, etamiphyllin, etofylline, proxyphylline, reproterol, theobromine-1-acetic acid, atropine, ipratropium bromide, flutropium bromide, oxitropium bromide, tiotropium bromide, budesonide, beclomethasone, ciclesonide, dexamethasone, flunisolide, fluticasone propionate, triamcinolone acetonide, prednisolone, methylprednisolone, hydrocortisone, cromolyn sodium, nedocromil sodium, montelukast, zafirlukast, pirfenidone, CPX, IBMX, cilomilast, roflumilast, pumafentrine, domitroban, israpafant, ramatroban, seratrodast, tiaramide, zileuton, ambrisentan, bosentan, enrasentan, sitaxsentan, tezosentan, iloprost, and treprostinil. 2. The composition of claim 1, wherein the condensation aerosol particles are characterized by less than 5% drug degradation products. 3. The composition of claim 2, wherein the condensation aerosol particles are characterized by less than 1% drug degradation products. 4. The composition of claim 1, wherein the drug composition comprises a drug that is in a free base form. 5. The composition of claim 1, wherein the drug composition comprises a drug that is in a free acid form. 6. The composition of claim 1, wherein the drug composition comprises at least two drugs. 7. The composition of claim 1, wherein the drug composition comprises a pharmaceutically acceptable excipient. 8. The composition of claim 1, wherein the condensation aerosol is devoid of excipients. 9. The composition of claim 1, wherein the condensation aerosol is devoid of propellants and organic solvents. 10. The composition of claim 1, wherein the condensation aerosol particles are characterized by increasing percentages of drug degradation products with increasing film thicknesses. 11. The composition of claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns. 12. The composition of claim 1, wherein the condensation aerosol is characterized by an MMAD of 1 to 5 microns. 13. The composition of claim 1, wherein the condensation aerosol is characterized by an MMAD of 10 to 100 nm. 14. The composition of claim 12, wherein the condensation aerosol is characterized by an MMAD of 1 to 3 microns. 15. The composition of claim 14, wherein the condensation aerosol particles are characterized by less than 5% drug degradation products. 16. The composition of claim 15, wherein the condensation aerosol particles are characterized by less than 1% drug degradation products. 17. The composition of claim 1, wherein the thin film has a thickness between 0.05 and 20 microns. 18. The composition of claim 17, wherein the thin film has a thickness between 0.5 and 5 microns. 19. A kit for delivering a condensation aerosol, the kit comprising: a) a thin film of a drug composition comprising a drug, on a solid support, and b) a device for providing the condensation aerosol, wherein the condensation aerosol is formed by heating the drug composition to produce a vapor, and condensing the vapor to form a condensation aerosol comprising the drug, wherein the condensation aerosol comprises particles that are characterized by less than 10% drug degradation products by weight, wherein the condensation aerosol has an MMAD of less than 5 microns, and wherein the drug is selected from the group consisting of albuterol, epinephrine, metaproterenol, terbutaline, pseudoephedrine hydrochloride, bambuterol, bitolterol, carbuterol, clenbuterol, clorprenalin, dioxethedrine, eprozinol, etefedrine, ethylnorepinephrine, fenoterol, fenspiride, hexoprenaline, isoetharine, isoproterenol, mabuterol, methoxyphenamine, pirbuterol, procaterol, protokylol, rimiterol, salmeterol, soterenol, tretoquinol, tulobuterol, theophylline, aminophylline, acefylline, bamifylline, doxofylline, dyphylline, etamiphyllin, etofylline, proxyphylline, reproterol, theobromine-1-acetic acid, atropine, ipratropium bromide, flutropium bromide, oxitropium bromide, tiotropium bromide, budesonide, beclomethasone, ciclesonide, dexamethasone, flunisolide, fluticasone propionate, triamcinolone acetonide, prednisolone, methylprednisolone, hydrocortisone, cromolyn sodium, nedocromil sodium, montelukast, zafirlukast, pirfenidone, CPX, IBMX, cilomilast, roflumilast, pumafentrine, domitroban, israpafant, ramatroban, seratrodast, tiaramide, zileuton, ambrisentan, bosentan, enrasentan, sitaxsentan, tezosentan, iloprost, and treprostinil. 20. The kit of claim 19, wherein the thin film has a thickness between 0.05 and 20 microns. 21. The kit of claim 19, wherein the thin film has a thickness between 0.5 and 5 microns. 22. The kit of claim 19, wherein the device comprises a heating element configured to heat the thin film to produce a vapor, and an enclosure allowing the vapor to condense to form a condensation aerosol. 23. The kit of claim 19, wherein the condensation aerosol comprises more than one drug. 24. The kit of claim 19, wherein the drug composition further comprises a pharmaceutically acceptable excipient. 25. The kit of claim 19, wherein the condensation aerosol has an MMAD of less than 3 microns. 26. The kit of claim 19, wherein the condensation aerosol has an MMAD of 1 to 5 microns. 27. The kit of claim 19, wherein the condensation aerosol has an MMAD of 10 to 100 nm. 28. The kit of claim 26, wherein the condensation aerosol has an MMAD of 1 to 3 microns. 29. The kit of claim 19, wherein the solid support is a metal foil. 30. The kit of claim 19, wherein the condensation aerosol particles are characterized by less than 5% drug degradation products. 31. The kit of claim 30, wherein the condensation aerosol particles are characterized by less than 1% drug degradation products. 32. The composition of claim 14, wherein the drug composition comprises a drug that is in a free base form. 33. The composition of claim 14, wherein the drug composition comprises a drug that is in a free acid form. 34. The composition of claim 14, wherein the drug composition comprises at least two drugs. 35. The composition of claim 14, wherein the drug composition comprises a pharmaceutically acceptable excipient. 36. The composition of claim 14, wherein the condensation aerosol is devoid of excipients. 37. The composition of claim 14, wherein the condensation aerosol is devoid of propellants and organic solvents. 38. The composition of claim 14, wherein the condensation aerosol particles are characterized by increasing percentages of drug degradation products with increasing film thicknesses. 39. The composition of claim 14, wherein the thin film has a thickness between 0.05 and 20 microns. 40. The composition of claim 39, wherein the thin film has a thickness between 0.5 and 5 microns. 41. The composition of claim 14, wherein the condensation aerosol is formed at a rate greater than 0.01 mg/s. 42. The composition of claim 41, wherein the condensation aerosol is formed at a rate greater than 0.9 mg/s. 43. The composition of claim 42, wherein the condensation aerosol is formed at a rate greater than 2.5 mg/s. 44. The composition of claim 1, wherein the condensation aerosol is formed at a rate greater than 0.01 mg/s. 45. The composition of claim 44, wherein the condensation aerosol is formed at a rate greater than 0.9 mg/s. 46. The composition of claim 45, wherein the condensation aerosol is formed at a rate greater than 2.5 mg/s.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (76)
Sands George H., 5HT 1 receptor agonists and metoclopramide for the treatment of migraine.
Clearman Jack F. (Blakely GA) Chiou Joseph J. (Clemmons NC) Williams Darrell D. (Winston-Salem NC) Casey William J. (Clemmons NC) Gentry Thomas L. (Winston-Salem NC) Squires William C. (Winston-Salem, Aerosol delivery article.
Roberts Donald L. (Winston-Salem NC) Morrison Carl C. (Winston-Salem NC) Brooks Johnny L. (Winston-Salem NC) Crooks Evon L. (Winston-Salem NC) Ingebrethsen Bradley J. (Winston-Salem NC), Aerosol delivery article.
Horvath, Raymond F.; Tran, Jennifer; De Lombaert, Stephane; Hodgetts, Kevin J.; Carpino, Philip A.; Griffith, David A., Certain alkylene diamine-substituted heterocycles.
Potter Dennis L. (Kernersville NC) Raker Mark L. (Clemmons NC) Ridings Henry T. (Lewisville NC) Sensabaugh ; Jr. Andrew J. (Winston-Salem NC) Westmoreland Amos E. (Winston-Salem NC) Woods Donna K. (W, Drug delivery article.
Sprinkel F. Murphy (Glen Allen VA) Das Amitabh (Midlothian VA) Fleischhauer Grier S. (Midlothian VA) Grollimund Everett C. (Midlothian VA) Houck ; Jr. Willie G. (Richmond VA) Lipowicz Peter J. (Midlo, Electrical lighter with a rotatable tobacco supply.
Higgins Charles T. (Richmond VA) Raymond Wynn R. (Chesterfield VA) Sprinkel Francis M. (Glen Allen VA), Electrical smoking article using liquid tobacco flavor medium delivery system.
Counts Mary E. (Richmond VA) LaRoy Bernard C. (Richmond VA) Losee ; Jr. D. Bruce (Richmond VA) Morgan Constance H. (Midlothian VA) Smith Ulysses (Midlothian VA) Sprinkel ; Jr. F. Murphy (Glen Allen V, Flavor generating article.
Counts Mary E. (Richmond VA) Hajaligol Mohammad R. (Richmond VA) Morgan Constance H. (Midlothian VA) Smith Ulysses (Midlothian VA) Sprinkel Francis M. (Glen Allen VA) Utsch Francis V. (Midlothian VA), Flavor-delivery article.
Weers Jeffry G. ; Dellamary Luis A. ; Tarara Thomas E. ; Trevino Leo A. ; Ranney Helen M., Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents.
Byron Peter R. (Richmond) Dalby Richard N. (Richmond VA), Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content.
Rubsamen Reid M. (Berkeley CA) Lloyd Lester J. (Orinda CA) Johansson Eric T. (Dublin CA), Lockout device for controlled release of drug from patient-activated dispenser.
Radhakrishnan Ramachandran (Fremont CA) Mihalko Paul J. (Fremont CA) Abra Robert M. (San Francisco CA), Method and apparatus for administering dehydrated liposomes by inhalation.
Banerjee Chandra K. (Pfafftown NC) Farrier Ernest G. (Winston-Salem NC) Ridings Henry T. (Lewisville NC) Sensabaugh ; Jr. Andrew J. (Winston-Salem NC) Shannon Michael D. (Lewisville NC) Shelar Gary R, Method for making aerosol generating cartridge.
Olsson Sven-Gunnar,SEX ; Rydgren Goran,SEX ; Larsson Anders,SEX ; Niininen Tarmo,SEX, Method for vaporizing an anesthetic liquid and vaporizer operating according to the method.
Serrano Mark A. (Greenwich CT) Houghton Kenneth S. (Midlothian VA) Lanzillotti Harry V. (Midlothian VA) Sanders Edward B. (Richmond VA) Lilly ; Jr. A. Clifton (Chesterfield VA) Hayward Charles R. (Mi, Smoking article.
Sutton Andrew D.,GBX ; Johnson Richard A.,GBX ; Senior Peter J.,GBX ; Heath David,GBX, Spray-dried microparticles and their use as therapeutic vehicles.
Lloyd Lester J. (Orinda CA) Lloyd Peter M. (Oakland CA) Rubsamen Reid M. (Berkeley CA) Schuster Jeffrey A. (Berkeley CA), Systems for the intrapulmonary delivery of aerosolized aqueous formulations.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Lu, Amy T.; Myers, Daniel J.; Rabinowitz, Joshua D.; Wensley, Martin J.; McKinney, Jeffrey A.; Zaffaroni, Alejandro C., Drug condensation aerosols and kits.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Lu, Amy T.; Myers, Daniel J.; Rabinowitz, Joshua D.; Wensley, Martin J.; McKinney, Jeffrey A.; Zaffaroni, Alejandro C., Drug condensation aerosols and kits.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Mufson, Daniel; Rogers, Daniel D.; Song, Soonho; Wensley, Martin J.; Myers, Daniel J.; McKinney, Jeffrey A.; Quintana, Reynaldo J.; Rabinowitz, Joshua D., Method of forming an aerosol for inhalation delivery.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Mufson, Daniel; Rogers, Daniel D.; Song, Soonho; Wensley, Martin J.; Myers, Daniel J.; McKinney, Jeffrey A.; Quintana, Reynaldo J.; Rabinowitz, Joshua D., Method of forming an aerosol for inhalation delivery.
Cross, Stephen D.; Herbette, Mathieu; Kelly, Andrew J. G.; Myers, Daniel J.; Shen, William W.; Timmons, Ryan D.; Tom, Curtis; Virgili, Justin M.; Wensley, Martin J., Multiple dose condensation aerosol devices and methods of forming condensation aerosols.
Hale, Ron L.; Lloyd, Peter M.; Lu, Amy T.; Rabinowitz, Joshua D.; Wensley, Martin J., Respiratory drug condensation aerosols and methods of making and using them.
Damani, Ramesh; Hale, Ron L.; Myers, Daniel J.; Quintana, Reynaldo J.; Solas, Dennis W.; Song, Soonho; Soni, Pravin; Tom, Curtis; Sharma, Kirshnamohan, Self-contained heating unit and drug-supply unit employing same.
Damani, Ramesh; Hale, Ron L.; Myers, Daniel J.; Quintana, Reynaldo J.; Solas, Dennis W.; Song, Soonho; Soni, Pravin; Tom, Curtis; Sharma, Krishnamohan, Self-contained heating unit and drug-supply unit employing same.
Damani, Ramesh; Hale, Ron L.; Myers, Daniel J.; Quintana, Reynaldo J.; Solas, Dennis W.; Song, Soonho; Soni, Pravin; Tom, Curtis; Sharma, Krishnamohan, Self-contained heating unit and drug-supply unit employing same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.